The efficacy of Ketamine in adult patients with Obsessive Compulsive Disorder with symptoms refractory to standard of care treatment. by Thornton, Brooke
Abstract
First line pharmacologic treatments for adult patients with 
Obsessive Compulsive Disorder (OCD) involve selective 
serotonin/norepinephrine reuptake inhibitors (SSRI/SNRIs). These 
drug classes often fail to deliver timely relief of symptoms as well 
as maintain longevity of symptom recurrence. This research 
analyzed the use of ketamine in adult patients suffering with OCD 
for the purposes of more efficacious management of symptoms. 
Although ketamine demonstrated a timelier relief of symptoms in 
some small clinical studies, its effects were ultimately unable to be 
sustained long term. Additionally, a wide range of adverse effects 
including dissociation, and rebound symptoms were observed. As 
a result, large scale longitudinal studies are needed to further 
evaluate all possible adverse effects in order to contract for patient 
safety. 
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Introduction
Methods
A literature search was completed through PubMed and Academic 
Search Ultimate on September 2018 and November 2018, 
respectively. A total of seven articles were selected based on their 
relevance to the research question, publication date, study design, 
outcomes, and results. 
A majority of the studies showed clinically and statistically 
significant relief of symptoms. There were two randomized 
controlled trials (RCTs) whose study designs appeared to be the 
most reliable, and contributed significantly to the small body of 
literature that currently exists on the topic. It should be noted 
ketamine has discernible sedative effects that are difficult to mask. 
As a result, it is difficult to perform truly double blinded studies and 
remains a significant obstacle for future study designs. 
Furthermore, there was a lack of longitudinal studies resulting in 
the long term effects of ketamine remaining widely unknown. More 
prospective RCTs need to be performed to determine the true 
efficacy of ketamine in this patient population. Lastly, a majority of 
the studies had small sample sizes resulting in a subsequently low 
power and low confidence interval. While ketamine and some novel 
NMDA receptors such as memantine did show promise in acutely 
decreasing symptoms, the level of variability of benefits between 
patients still remains a primary concern. Primarily we have learned:
Discussion	
Table 1. Comparison of Results  
Results	
The efficacy of Ketamine in adult patients with Obsessive 
Compulsive Disorder with symptoms refractory to standard 
of care treatment.
It is difficult to assess the efficacy of ketamine primarily due to its 
sedative properties. There is a high likelihood that the reported 
reduction in symptomatology post-infusion may have been a result 
of such elements. Additionally, there was a vast range of clinical 
benefits between studies regardless of similarities in patient 
populations. While the current evidence is not strong enough to 
recommend ketamine for clinical practice at this time, the anti-
obsessional effects of ketamine and NMDA receptor antagonists 
does show potential. Future research is warranted to establish the 
parameters of ketamine’s efficacy in order to better contract for 
patient safety. With larger clinical RCTs, a stronger argument can 
be made for future modification of guidelines for patient care in this 
population.
Conclusion
The evidence collected by each of the studies 
demonstrated statistically significant improvement in 
symptoms due to ketamine based on the Yale-Brown 
Obsessive Compulsive Scale (Y-BOCS). There was also 
evidence that ketamine allowed for better engagement in 
psychotherapy, which in turn allowed for clinically 
significant relief of symptoms. There was clinical evidence 
that demonstrated the effects of ketamine could be 
prolonged by pharmaceutical methods, but the length of 
prolongation varied wildly among participants. Ultimately, 
the clinical effects of ketamine varied significantly. The 
side effects of ketamine ranged from mild dissociation, to 
distortion in reality with rebound worsening of symptoms 
hours to days post-infusion. Additionally, there are no large 
scale randomized controlled trials to date involving the use 
of ketamine for the treatment of adult patients with OCD.
Study	
Reduction	in	
Y-BOCS
Adverse	side	effects	at	time	of	
treatment Carry-over	effects	of	ketamine
Recurrence	of	
symptoms
Adams	TG,	Bloch	
MH,	Pittenger	C.	
2017
S S NS S
Marinova	Z,	Chuang	
DM,	Fineberg	N.	
2017
S S N/A S
Niciu	MJ,	Grunschel	
BD,	Corlett	PR,	et	al.	
2013
S S S NS
Rodriguez	CI,	
Kegeles	LS,	
Levinson	A,	et	al.	
2015
S N/A N/A N/A
Rodriguez	CI,	
Kegeles	LS,	
Levinson	A,	et	al.	
2013
S S S NS
Rodriguez	CI,	
Levinson	A,	
Zwerling	J,	et	al.	
2016
S S NS NS
Rodriguez	CI,	
Wheaton	M,	
Zwerling	J,	et	al.	
2018	
S NS NS S
Key
S=	statistically	
significant
NS=	not	significant	
N/A=	not	applicable	
S=	>/=	35%	
reduction	in	Y-
BOCS	scale
NS=	No	or	<20%	
reduction	in	Y-
BOCS	scale
S=	3+	ketamine	related	side	
effects
NS=	no	recorded	side	effects
S=	ketamine	caused	sx	to	
worsen	once	effects	wore	off	
NS=	ketamine	did	not	trigger	
late	onset	worsening	of	sx
S=	symptoms	
did	not	recurr	
for	more	than	
1	week	
NS=	
symptoms	
returned	
immediately	
or	<1	week	
after	last	
ketamine	
administration	
Key: S=Significant    NS=Not significant 
OCD is a mental illness that causes a patient to suffer with 
debilitating obsessions and compulsions resulting in a negative 
impact on their quality of life. It was not until the Diagnostic and 
Statistical Manual of Mental Health Disorders 5th edition (DSM-5) 
published in 2013 that OCD was given a category separate from 
anxiety disorders. As a result, many of these patients had 
historically been treated identically to patients with anxiety and/or 
depression. This is detrimental to the care of patients with OCD as 
the clinical manifestations tend to be more distinctive and refractory 
than other mental illnesses. Pharmacologic treatment that is 
capable of delivering a timelier relief of OCD symptoms as well as 
maintaining longevity of recurrence has not been established. This 
research hopes to determine effectiveness and timeliness of 
ketamine in adult patients suffering with OCD for the purposes of 
efficacious management of symptoms refractory to traditional 
SSRI/SNRI treatments. 
Ketamine	has	an	acute	onset	of	action	which	plays	a	role	in	the	
immediate	relief	of	symptoms	demonstrated.
Other	NMDA	receptors	antagonists	also	seem	to	have	an	anti-
obsessional	effect	on	patients.
NMDA	agents have	shown	potential	for	increasing	compliance	and	
participation	in	CBT	sessions.	This	allows patients	to	develop	long-
term	non-pharmacologic	coping	mechanisms.	
